Reata Pharmaceuticals, Inc.
(NASDAQ GM: RETA)
Rigrodsky Law, P.A. is investigating Reata Pharmaceuticals, Inc. (“Reata”) regarding possible breaches of fiduciary duties and other violations of law related to Reata’s agreement to be acquired by Biogen Inc. Under the terms of the agreement, Reata shareholders will receive $172.50 per share in cash.